Want to see AU:SOM full AI Analyst Report?
SOM Stock Chart & Stats
AU$0.56
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.56
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.44 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$100.78M
Enterprise ValueAU$159.83
Total Cash (Recent Filing)AU$18.03M
Total Debt (Recent Filing)AU$14.01M
Price to Earnings (P/E)―
Beta1.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,083,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSomnomed’s revenue growth (latest period +11.22%) demonstrates expanding adoption of its oral appliance therapy across markets. Persistent top-line increases support durable demand, enabling scale benefits in manufacturing and distribution and underpinning multi-quarter revenue predictability.
High Gross MarginA roughly 60% gross margin indicates structural unit-level profitability from device manufacturing. High gross margins provide cushion to absorb SG&A and R&D, and improve the company’s ability to invest in clinical validation and provider networks even while operating profit is still negative.
Improving Cash GenerationA >562% rise in free cash flow and positive operating cash flow despite net losses show strong cash conversion. This durable cash generation reduces refinancing risk, supports ongoing operations and measured expansion, and gives management flexibility to fund growth initiatives without heavy new debt.
Bears Say
Persistent LossesDespite revenue growth and healthy gross margins, persistent negative net profit and EBIT margins indicate the company isn’t converting sales into sustainable operating profits. Over months this can limit reinvestment, constrain strategic initiatives, and increase reliance on external capital to fund expansion.
Weak Return On EquityNegative ROE shows the company is not generating adequate returns on shareholders’ capital. Even with low leverage, capital inefficiency can impede investor confidence and make raising equity or debt more costly, restricting long-term ability to scale commercial and clinical programs.
Channel-Dependent Revenue ModelRevenue relies on per-device orders routed through dental and sleep clinician channels. This provider-dependent model limits direct pricing control and ties growth to clinician adoption, reimbursement frameworks and dentist throughput—factors that can slow scale and amplify the impact of persistent losses.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.43 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$100.78M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Overvalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,083,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOM Company Deck
SOM Earnings Call
Q2 2026
0:00 / 0:00